SSC 2026 Guidelines now available — 129 adult & 61 pediatric recommendations View guidelines →
Evidence-based guideline for recognition, grading, and management of immune-related adverse events (irAEs) across all organ systems in patients receiving checkpoint inhibitor immunotherapy.
Management of immune-mediated hematologic toxicities, ophthalmologic irAEs, combination immunotherapy toxicity profiles, rechallenge criteria, preexisting autoimmune disease, special populations, multidisciplinary triggers, and patient education.
Grade-based management of immune-mediated myocarditis, pericarditis, neurologic toxicities (myasthenia gravis, encephalitis, Guillain-Barre, neuropathy), nephritis, inflammatory arthritis, and myositis.
Grade-based management of immune-mediated endocrine toxicities (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes) and pneumonitis including workup, corticosteroid protocols, hormone replacement, and immunosuppressive escalation.
Grade-based management of immune-mediated dermatologic toxicities (rash, pruritus, bullous pemphigoid, SJS/TEN), colitis/diarrhea, and hepatitis including workup, corticosteroid protocols, and immunosuppressive escalation.
Classes of immune checkpoint inhibitors, mechanism and epidemiology of irAEs, CTCAE grading, general management framework, corticosteroid protocols, immunosuppressive escalation, and infusion reactions.